Datopotamab deruxtecan

Specification

• Cat#: THP-3356
• Product Name: Datopotamab deruxtecan
• Description: Datopotamab deruxtecan (DS-1062) solution is a TROP2-targeted antibody-drug conjugate (ADC) with human TROP2 Kd of 0.74 nmol/L. Datopotamab deruxtecan solution consists of the antibody Datopotamab and the toxic molecule-linker conjugate Deruxtecan. Datopotamab deruxtecan solution binds TROP2, triggers internalization and lysosomal trafficking and releases DXd topoisomerase I inhibitor payload. Datopotamab deruxtecan solution disrupts DNA function, induces DNA damage, apoptosis, and bystander killing of tumor microenvironment cells. Datopotamab deruxtecan solution can be used in research related to triple-negative breast cancer, gastric cancer, and non-small cell lung cancer
• Species: Human
• Source: CHO
• Purity: 98.46% by SEC-HPLC
• Storage: Store at low temperature. Store at -20 centigrade.
• Appearance: Liquid
• Formulation: Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based).

Pharmaceutical Information

• Applications: ELISA; FCM; Functional assay